Home > Insider Trading > Filing (0001213900-22-024052)

Filing Details

Accession Number:: 0001213900-22-024052
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-05-04 20:01:39
Reporting Period:: 2022-05-02

Accepted Time:: 2022-05-04 20:01:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1750117	Vivo Capital Fund Ix, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301		No	No	Yes	No
1750698	Vivo Capital Ix, Llc	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto, CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-05-02	41,800	$15.19	2,945,531	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-05-03	451,418	$13.25	2,494,113	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-05-04	19,738	$12.67	2,474,375	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.92, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.05 to $13.89, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 12.25 to $13.00 inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.